[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"other-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:other-carcinoma":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100558498","phase-2-pemigatinib-and-immune-checkpoint-inhibitor-treated-fgfr123-alteration-advanced-solid-tumor-100558498",false,"NCT06551896","Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1\u002F2\u002F3 Alteration Advanced Solid Tumor","Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1\u002F2\u002F3 Alteration Advanced Solid Tumor: a Single Arm, Multiple Center, Phase II Study (Pigeon Study)","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Histologically or cytologically confirmed unresectable advanced solid tumors with failure or intolerance to standard treatments;\n* At least one measurable lesion per RECIST v1.1 criteria;\n* Gene testing confirms FGFR1\u002F2\u002F3 variants, including but not limited to mutations, fusions\u002Frearrangements in solid tumors;\n* Patients have not previously used specific small molecule multi-target inhibitors of the FGFR pathway, as assessed by investigators, and have been treated with immune checkpoint inhibitors;\n* ECOG performance status of 0-1;\n* Expected survival time \\> 3 months;\n* Laboratory criteria:\n\n  1. Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹\u002FL in the past 14 days without granulocyte colony-stimulating factor;\n  2. Platelets ≥ 100 x 10⁹\u002FL without transfusion in the past 14 days;\n  3. Hemoglobin \\> 9 g\u002FdL in the last 14 days without transfusion or erythropoietin;\n  4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN), or total bilirubin \\> ULN but direct bilirubin ≤ ULN;\n  5. AST, ALT ≤ 2.5 x ULN (≤ 5 x ULN in patients with liver metastasis);\n  6. Serum creatinine ≤ 1.5 x ULN and creatinine clearance (Cockcroft-Gault) ≥ 50 ml\u002Fmin;\n  7. Good coagulation function, defined as INR or PT ≤ 1.5 x ULN. If on anticoagulant therapy, PT should be within the therapeutic range of anticoagulants;\n* Female subjects of reproductive age must have a negative urine or serum pregnancy test within 3 days prior to the first dose (Cycle 1, Day 1). If the urine test is inconclusive, a blood test is required. Non-reproductive females are defined as post-menopausal for at least one year or surgically sterile;\n* Subjects with reproductive potential must use contraception with an annual failure rate of less than 1% during treatment and for 120 days after the last study drug dose (or 180 days after the last chemotherapy dose).\n\nExclusion Criteria:\n\n* Diagnosis of other malignancies within 3 years before the first dose, except for certain treated skin carcinomas and in-situ carcinomas;\n* Previous treatment with selective FGFR inhibitors;\n* Receipt of other investigational drugs within 21 days or antitumor drugs within 14 days before the first dose;\n* Unresolved toxicity from prior treatments unless ≤ Grade 1 or related to alopecia or fatigue;\n* Known symptomatic CNS metastasis or carcinomatous meningitis. Stable patients post-treatment with no evidence of progression may be eligible if steroid-free for at least 14 days;\n* History of allogeneic organ or hematopoietic stem cell transplantation;\n* Abnormal laboratory parameters:\n\n  1. Serum phosphate \\> 1.5 x ULN;\n  2. Elevated serum calcium or albumin-adjusted calcium outside the reference range;\n* Known HIV infection or positive HIV test;\n* Active or poorly controlled serious infection;\n* Need for drainage treatment for pleural effusion, ascites, or pericardial effusion;\n* Active hepatitis B or C infection with high viral load, or positive HBsAg or anti-HCV antibodies. Patients on antiviral therapy must meet lower thresholds;\n* Significant uncontrolled heart disease, including recent MI, severe heart failure, or uncontrolled arrhythmias;\n* Clinically significant ECG changes or history of significant cardiac issues; Screening QTcF interval \\> 480 ms, or JTc interval if applicable, must be ≤ 340 ms;\n* Uncontrolled hypertension despite treatment;\n* Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh grade B or higher cirrhosis;\n* Major surgery within 4 weeks before the first dose or planned major surgery during the study;\n* Unresolved complications from prior surgery;\n* Pregnant or breastfeeding women, or those planning to become pregnant during the study period and for safety follow-up;\n* Radiotherapy within 4 weeks before the first dose, except for non-CNS palliative radiotherapy with a 2-week washout period;\n* History of systemic electrolyte imbalance or ectopic soft tissue calcification;\n* Clinically significant corneal or retinal disease;\n* Use of potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives before the first dose;","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1\u002F2\u002F3 variant advanced solid tumors.",[26,27,28,29,30,31],"Urothelial Carcinoma","Breast Neoplasms","Lung Cancer","Gastric Cancer","Soft Tissue Sarcoma","Other Carcinoma",[33,34,35],"Pemigatinib","FGFR1\u002F2\u002F3 alteration","Solid tumor","NOT_YET_RECRUITING","2024-08-11",{"date":39,"type":40},"2024-08-13","ACTUAL",{"date":42,"type":20},"2024-08-15",{"date":44,"type":20},"2026-12-31",{"name":46,"class":47},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100524998","online-adaptive-radiotherapy-using-a-novel-linear-accelerator-ethos-100524998","NCT06116019","Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)","A Prospective Study on Online Adaptive Radiotherapy (ART) Using the ETHOS Linear Accelerator for Various Tumor Entities and the Feasibility of Integrating Multi-Parametric Patient Data Into the Adaptive Workflow","ART-02","Inclusion Criteria:\n\n* Adult patients (\\>18 years)\n* All tumor entities with an indication for radiotherapy and\u002For chemoradiotherapy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients who are not capable of giving consent",{"count":57,"type":20},649,"OBSERVATIONAL","The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian\u002FSHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).",[61,62,63,64,65,66,67,68,31],"Prostate Cancer","Head and Neck Cancer","NSCLC","SCLC","Esophageal Cancer","Bladder Cancer","Rectum Cancer","Cervix Cancer",[70,71,72,73],"online adaptive radiation therapy","ART","cone beam CT","ePROMS","RECRUITING","2023-10-30",{"date":77,"type":40},"2023-11-03",{"date":79,"type":40},"2023-10-11",{"date":81,"type":20},"2027-10-09",{"name":83,"class":47},"Charite University, Berlin, Germany",1]